{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T04:33:51Z","timestamp":1793853231652,"version":"4.6.1"},"reference-count":43,"publisher":"American Society of Hematology","issue":"3","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2008,2,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The prognostic relevance of FLT3 D835\/I836 mutations (FLT3-TKD) in cytogenetically normal acute myeloid leukemia (CN-AML) remains to be established. After excluding patients with FLT3 internal tandem duplications, we compared treatment outcome of 16 de novo CN-AML patients with FLT3-TKD with that of 123 patients with wild-type FLT3 (FLT3-WT), less than 60 years of age and similarly treated on Cancer and Leukemia Group B protocols. All FLT3-TKD+ patients and 85% of FLT3-WT patients achieved a complete remission (P = .13). Disease-free survival (DFS) of FLT3-TKD+ patients was worse than DFS of FLT3-WT patients (P = .01; estimated 3-year DFS rates, 31% vs 60%, respectively). In a multivariable analysis, FLT3-TKD was associated with worse DFS (P = .02) independent of NPM1 status and percentage of bone marrow blasts. To gain further biologic insights, a gene-expression signature differentiating FLT3-TKD+ from FLT3-WT patients was identified. The signature (333 probe sets) included overexpression of VNN1, C3AR1, PTPN6, and multiple other genes involved in monocarboxylate transport activity, and underexpression of genes involved in signal transduction regulation. These associations with outcome, other prognostic markers, and the elucidated expression signature enhance our understanding of FLT3-TKD\u2013associated biology and may lead to development of novel therapies that improve clinical outcome of CN-AML patients with FLT3-TKD.<\/jats:p>","DOI":"10.1182\/blood-2007-08-107946","type":"journal-article","created":{"date-parts":[[2007,10,17]],"date-time":"2007-10-17T03:40:39Z","timestamp":1192592439000},"page":"1552-1559","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":224,"title":["FLT3 D835\/I836 mutations are associated with poor disease-free survival and a distinct gene-expression signature among younger adults with de novo cytogenetically normal acute myeloid leukemia lacking FLT3 internal tandem duplications"],"prefix":"10.1182","volume":"111","author":[{"given":"Susan P.","family":"Whitman","sequence":"first","affiliation":[{"name":"Division of Hematology and Oncology, Department of Internal Medicine, Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy S.","family":"Ruppert","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Department of Internal Medicine, Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio;"},{"name":"Cancer and Leukemia Group B Statistical Center, Duke University Medical Center, Durham, NC;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael D.","family":"Radmacher","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Department of Internal Medicine, Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio;"},{"name":"Cancer and Leukemia Group B Statistical Center, Duke University Medical Center, Durham, NC;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krzysztof","family":"Mr\u00f3zek","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Department of Internal Medicine, Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Paschka","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Department of Internal Medicine, Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Langer","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Department of Internal Medicine, Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio;"},{"name":"Division of Human Cancer Genetics, Department of Microbiology, Virology, Immunology, and Medical Genetics, Comprehensive Cancer Center, The Ohio State University, Columbus;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia D.","family":"Baldus","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Charit\u00e9 University Hospital, Campus Benjamin Franklin, Berlin, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Wen","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Department of Internal Medicine, Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederick","family":"Racke","sequence":"additional","affiliation":[{"name":"Department of Pathology, The Ohio State University, Columbus;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bayard L.","family":"Powell","sequence":"additional","affiliation":[{"name":"Section on Hematology and Oncology, Comprehensive Cancer Center of Wake Forest University, Winston-Salem, NC;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan E.","family":"Kolitz","sequence":"additional","affiliation":[{"name":"Department of Medicine, North Shore University Hospital, Manhasset, NY; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard A.","family":"Larson","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael A.","family":"Caligiuri","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Department of Internal Medicine, Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio;"},{"name":"Division of Human Cancer Genetics, Department of Microbiology, Virology, Immunology, and Medical Genetics, Comprehensive Cancer Center, The Ohio State University, Columbus;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guido","family":"Marcucci","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Department of Internal Medicine, Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio;"},{"name":"Division of Human Cancer Genetics, Department of Microbiology, Virology, Immunology, and Medical Genetics, Comprehensive Cancer Center, The Ohio State University, Columbus;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clara D.","family":"Bloomfield","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Department of Internal Medicine, Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2019111723285192600_B1","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1634\/stemcells.2005-0519","article-title":"FMS-like tyrosine kinase 3 in normal hematopoiesis and acute myeloid leukemia.","volume":"24","author":"Parcells","year":"2006","journal-title":"Stem Cells"},{"key":"2019111723285192600_B2","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1182\/blood-2006-06-001149","article-title":"Clinical relevance of mutations and gene-expression changes in adult acute myeloid leukemia with normal cytogenetics: are we ready for a prognostically prioritized molecular classification?","volume":"109","author":"Mr\u00f3zek","year":"2007","journal-title":"Blood"},{"key":"2019111723285192600_B3","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1182\/blood-2004-02-0660","article-title":"Identification of a novel activating mutation (Y842C) within the activation loop of FLT3 in patients with acute myeloid leukemia (AML).","volume":"105","author":"Kindler","year":"2005","journal-title":"Blood"},{"key":"2019111723285192600_B4","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1038\/sj.leu.2404374","article-title":"FLT3 K663Q is a novel AML\u2013associated oncogenic kinase: determination of biochemical properties and sensitivity to Sunitinib (SU11248).","volume":"20","author":"Schittenhelm","year":"2006","journal-title":"Leukemia"},{"key":"2019111723285192600_B5","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.lab.2005.03.005","article-title":"Specific detection of Flt3 point mutations by highly sensitive real-time polymerase chain reaction in acute myeloid leukemia.","volume":"145","author":"Scholl","year":"2005","journal-title":"J Lab Clin Med"},{"key":"2019111723285192600_B6","doi-asserted-by":"crossref","first-page":"3700","DOI":"10.1182\/blood-2005-06-2596","article-title":"Point mutations in the juxtamembrane domain of FLT3 define a new class of activating mutations in AML.","volume":"107","author":"Reindl","year":"2006","journal-title":"Blood"},{"key":"2019111723285192600_B7","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1182\/blood-2002-11-3441","article-title":"Sensitivity toward tyrosine kinase inhibitors varies between different activating mutations of the FLT3 receptor.","volume":"102","author":"Grundler","year":"2003","journal-title":"Blood"},{"key":"2019111723285192600_B8","doi-asserted-by":"crossref","first-page":"4792","DOI":"10.1182\/blood-2004-11-4430","article-title":"FLT3-ITD and tyrosine kinase domain mutants induce 2 distinct phenotypes in a murine bone marrow transplantation model.","volume":"105","author":"Grundler","year":"2005","journal-title":"Blood"},{"key":"2019111723285192600_B9","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1182\/blood-2004-07-2942","article-title":"AML\u2013associated Flt3 kinase domain mutations show signal transduction differences compared with Flt3 ITD mutations.","volume":"106","author":"Choudhary","year":"2005","journal-title":"Blood"},{"key":"2019111723285192600_B10","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1532\/IJH97.06071","article-title":"Biology, clinical relevance, and molecularly targeted therapy in acute leukemia with FLT3 mutation.","volume":"83","author":"Kiyoi","year":"2006","journal-title":"Int J Hematol"},{"key":"2019111723285192600_B11","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1200\/JCO.2005.01.6253","article-title":"BAALC expression and FLT3 internal tandem duplication mutations in acute myeloid leukemia patients with normal cytogenetics: prognostic implications.","volume":"24","author":"Baldus","year":"2006","journal-title":"J Clin Oncol"},{"key":"2019111723285192600_B12","doi-asserted-by":"crossref","first-page":"6285","DOI":"10.1200\/JCO.2005.05.010","article-title":"Genetics of myeloid malignancies: pathogenetic and clinical implications.","volume":"23","author":"Fr\u00f6hling","year":"2005","journal-title":"J Clin Oncol"},{"key":"2019111723285192600_B13","doi-asserted-by":"crossref","first-page":"4372","DOI":"10.1182\/blood-2002-05-1440","article-title":"Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm.","volume":"100","author":"Fr\u00f6hling","year":"2002","journal-title":"Blood"},{"key":"2019111723285192600_B14","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1182\/blood.V100.1.59","article-title":"Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease.","volume":"100","author":"Schnittger","year":"2002","journal-title":"Blood"},{"key":"2019111723285192600_B15","doi-asserted-by":"crossref","first-page":"4326","DOI":"10.1182\/blood.V99.12.4326","article-title":"Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis.","volume":"99","author":"Thiede","year":"2002","journal-title":"Blood"},{"key":"2019111723285192600_B16","first-page":"7233","article-title":"Absence of the wild-type allele predicts poor prognosis in adult de novo acute myeloid leukemia with normal cytogenetics and the internal tandem duplication of FLT3: a Cancer and Leukemia Group B study.","volume":"61","author":"Whitman","year":"2001","journal-title":"Cancer Res"},{"key":"2019111723285192600_B17","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1016\/j.leukres.2005.05.013","article-title":"Analysis of FLT3 internal tandem duplication and D835 mutations in Chinese acute leukemia patients.","volume":"29","author":"Wang","year":"2005","journal-title":"Leuk Res"},{"key":"2019111723285192600_B18","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1111\/j.1600-0609.2004.00225.x","article-title":"Clinical impact of internal tandem duplications and activating point mutations in FLT3 in acute myeloid leukemia in elderly patients.","volume":"72","author":"Andersson","year":"2004","journal-title":"Eur J Haematol"},{"key":"2019111723285192600_B19","first-page":"19","article-title":"Incidence and prognostic value of FLT3 internal tandem duplication and D835 mutations in acute myeloid leukemia.","volume":"88","author":"Moreno","year":"2003","journal-title":"Haematologica"},{"key":"2019111723285192600_B20","doi-asserted-by":"crossref","first-page":"4290","DOI":"10.1200\/JCO.2004.11.106","article-title":"Dose escalation studies of cytarabine, daunorubicin, and etoposide with and without multidrug resistance modulation with PSC-833 in untreated adults with acute myeloid leukemia younger than 60 years: final induction results of Cancer and Leukemia Group B study 9621.","volume":"22","author":"Kolitz","year":"2004","journal-title":"J Clin Oncol"},{"key":"2019111723285192600_B21","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1182\/blood.V106.11.407.407","article-title":"A randomized comparison of induction therapy for untreated acute myeloid leukemia (AML) in patients < 60 years using P-glycoprotein (Pgp) modulation with Valspodar (PSC833): preliminary results of Cancer and Leukemia Group B study 19808 [abstract 407].","volume":"106","author":"Kolitz","year":"2005","journal-title":"Blood"},{"key":"2019111723285192600_B22","doi-asserted-by":"crossref","first-page":"4325","DOI":"10.1182\/blood-2002-03-0772","article-title":"Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461).","volume":"100","author":"Byrd","year":"2002","journal-title":"Blood"},{"key":"2019111723285192600_B23","doi-asserted-by":"crossref","first-page":"2434","DOI":"10.1182\/blood.V97.8.2434","article-title":"Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies.","volume":"97","author":"Yamamoto","year":"2001","journal-title":"Blood"},{"key":"2019111723285192600_B24","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1182\/blood-2006-04-015826","article-title":"FLT3 tyrosine kinase domain mutations are biologically distinct from and have a significantly more favorable prognosis than FLT3 internal tandem duplications in patients with acute myeloid leukemia.","volume":"110","author":"Mead","year":"2007","journal-title":"Blood"},{"key":"2019111723285192600_B25","first-page":"55","article-title":"Rearrangement of ALL1 (MLL) in acute myeloid leukemia with normal cytogenetics.","volume":"58","author":"Caligiuri","year":"1998","journal-title":"Cancer Res"},{"key":"2019111723285192600_B26","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1182\/blood-2005-01-0204","article-title":"The MLL partial tandem duplication: evidence for recessive gain-of-function in acute myeloid leukemia identifies a novel patient subgroup for molecular-targeted therapy.","volume":"106","author":"Whitman","year":"2005","journal-title":"Blood"},{"key":"2019111723285192600_B27","doi-asserted-by":"crossref","first-page":"3740","DOI":"10.1182\/blood-2005-05-2164","article-title":"Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations.","volume":"106","author":"D\u00f6hner","year":"2005","journal-title":"Blood"},{"key":"2019111723285192600_B28","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1182\/blood-2003-02-0359","article-title":"BAALC expression predicts clinical outcome of de novo acute myeloid leukemia patients with normal cytogenetics: a Cancer and Leukemia Group B study.","volume":"102","author":"Baldus","year":"2003","journal-title":"Blood"},{"key":"2019111723285192600_B29","doi-asserted-by":"crossref","first-page":"9234","DOI":"10.1200\/JCO.2005.03.6137","article-title":"Overexpression of the ETS-related gene, ERG, predicts a worse outcome in acute myeloid leukemia with normal karyotype: a Cancer and Leukemia Group B study.","volume":"23","author":"Marcucci","year":"2005","journal-title":"J Clin Oncol"},{"key":"2019111723285192600_B30","doi-asserted-by":"crossref","first-page":"3337","DOI":"10.1200\/JCO.2007.10.8720","article-title":"High expression levels of the ETS-related gene, ERG, predict adverse outcome and improve molecular risk-based classification of cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study.","volume":"25","author":"Marcucci","year":"2007","journal-title":"J Clin Oncol"},{"key":"2019111723285192600_B31","doi-asserted-by":"crossref","first-page":"e15","DOI":"10.1093\/nar\/gng015","article-title":"Summaries of Affymetrix GeneChip probe level data.","volume":"31","author":"Irizarry","year":"2003","journal-title":"Nucleic Acids Res"},{"key":"2019111723285192600_B32","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/ng0502-19","article-title":"GenMAPP, a new tool for viewing and analyzing microarray data on biological pathways.","volume":"31","author":"Dahlquist","year":"2002","journal-title":"Nat Genet"},{"key":"2019111723285192600_B33","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.exphem.2005.01.004","article-title":"Src family tyrosine kinases are activated by Flt3 and are involved in the proliferative effects of leukemia\u2013associated Flt3 mutations.","volume":"33","author":"Robinson","year":"2005","journal-title":"Exp Hematol"},{"key":"2019111723285192600_B34","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1038\/sj.leu.2404547","article-title":"Lyn is an important component of the signal transduction pathway specific to FLT3\/ITD and can be a therapeutic target in the treatment of AML with FLT3\/ITD.","volume":"21","author":"Okamoto","year":"2007","journal-title":"Leukemia"},{"key":"2019111723285192600_B35","doi-asserted-by":"crossref","first-page":"3699","DOI":"10.1182\/blood-2004-07-2924","article-title":"Flt3 tandem duplication mutations cooperate with Wnt signaling in leukemic signal transduction.","volume":"105","author":"Tickenbrock","year":"2005","journal-title":"Blood"},{"key":"2019111723285192600_B36","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1053\/shem.2002.36921","article-title":"Molecular genetics of human leukemias: new insights into therapy.","volume":"39","author":"Gilliland","year":"2002","journal-title":"Semin Hematol"},{"key":"2019111723285192600_B37","first-page":"855","article-title":"Targeting epigenetic changes in acute myeloid leukemia.","volume":"3","author":"Blum","year":"2005","journal-title":"Clin Adv Hematol Oncol"},{"key":"2019111723285192600_B38","first-page":"91","article-title":"Valproic acid: an old drug newly discovered as inhibitor of histone deacetylases.","volume":"83","author":"Gottlicher","year":"2004","journal-title":"Ann Hematol"},{"key":"2019111723285192600_B39","doi-asserted-by":"crossref","first-page":"3784","DOI":"10.1182\/blood-2002-10-3233","article-title":"Functional receptor for C3a anaphylatoxin is expressed by normal hematopoietic stem\/progenitor cells, and C3a enhances their homing-related responses to SDF-1.","volume":"101","author":"Reca","year":"2003","journal-title":"Blood"},{"key":"2019111723285192600_B40","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1084\/jem.20061640","article-title":"Vanin-1 licenses inflammatory mediator production by gut epithelial cells and controls colitis by antagonizing peroxisome proliferator-activated receptor \u03b3 activity.","volume":"203","author":"Berruyer","year":"2006","journal-title":"J Exp Med"},{"key":"2019111723285192600_B41","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1172\/JCI200419557","article-title":"Vanin-1\u2212\/\u2212 mice show decreased NSAID- and Schistosoma-induced intestinal inflammation associated with higher glutathione stores.","volume":"113","author":"Martin","year":"2004","journal-title":"J Clin Invest"},{"key":"2019111723285192600_B42","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1093\/intimm\/11.9.1371","article-title":"Protein tyrosine kinase Lyn mediates apoptosis induced by topoisomerase II inhibitors in DT40 cells.","volume":"11","author":"Maruo","year":"1999","journal-title":"Int Immunol"},{"key":"2019111723285192600_B43","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1016\/j.exphem.2006.05.019","article-title":"Constitutive c-jun N-terminal kinase activity in acute myeloid leukemia derives from Flt3 and affects survival and proliferation.","volume":"34","author":"Hartman","year":"2006","journal-title":"Exp Hematol"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/111\/3\/1552\/1306454\/zh800308001552.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/111\/3\/1552\/1306454\/zh800308001552.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,27]],"date-time":"2020-04-27T07:05:49Z","timestamp":1587971149000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/111\/3\/1552\/25465\/FLT3-D835I836-mutations-are-associated-with-poor"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,2,1]]},"references-count":43,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2008,2,1]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2007-08-107946","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,2,1]]}}}